Ahammune Biosciences, a promising biotech startup based in Pune, has successfully raised $5 million in a Series A funding round led by pi Ventures. The round also attracted participation from several notable investors, including Capital2B, Colossa Ventures, Bipin Agarwal, Unicornus Maximus LLP, as well as existing supporters Ideaspring Capital, Kotak Alternate Assets, Legacy Assets LLP, and IAN. This latest funding round comes on the heels of an earlier investment of approximately $3 million raised from existing and new investors.
The newly acquired funds will be strategically allocated to advance Phase II human clinical trials for drug candidates targeting vitiligo, a chronic skin condition characterized by the loss of skin pigment. Additionally, the funding will support the expansion of Ahammune’s patent portfolio and further enhance its research and development (R&D) efforts focused on other immune-mediated skin diseases.
Founded in 2016 by Parul Ganju and Krishnamurthy Natarajan, Ahammune Biosciences is a clinical-stage therapeutics company dedicated to developing innovative solutions for treating skin diseases. The company’s approach centres on its proprietary small molecule therapeutics platform, designed to target and improve skin health. Ahammune’s mission is to provide cost-effective and innovative treatments that address unmet needs within the dermatology field, thereby revolutionizing the future of therapies for skin diseases.
The company’s initial program is dedicated to creating a groundbreaking drug candidate for vitiligo. Ahammune asserts that its small-molecule drug candidate operates without causing generalized immunosuppression and features a first-in-class mechanism of action. This unique approach not only halts the spread of vitiligo patches but also stimulates the function of melanocytes—cells responsible for producing skin colour—thereby inducing repigmentation.
Beyond vitiligo, Ahammune is actively developing a robust pipeline of patented molecules aimed at addressing other dermatological and autoimmune diseases. The company is committed to expanding its patent portfolio around its proprietary technology and is focusing on developing treatments that target key cellular processes influencing skin health and immunity. Furthermore, Ahammune is seeking strategic partnerships with pharmaceutical companies to co-develop its assets, maximizing their reach and commercial potential.
With this significant funding boost, Ahammune Biosciences is well-positioned to make strides in the dermatological therapeutics space, aiming to transform the treatment landscape for skin conditions and improve the quality of life for countless individuals affected by these diseases.
